Ruby Smith Whelan

ORCID: 0000-0003-4389-8685
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Bladder and Urothelial Cancer Treatments
  • Cancer Research and Treatments
  • Urinary and Genital Oncology Studies
  • Head and Neck Cancer Studies
  • Urinary Bladder and Prostate Research
  • Urinary Tract Infections Management
  • Oral health in cancer treatment
  • Otolaryngology and Infectious Diseases
  • Obstructive Sleep Apnea Research
  • Cancer Diagnosis and Treatment
  • Streptococcal Infections and Treatments

University of Leeds
2024-2025

Newcastle University
2022-2023

773 Background: BCG-unresponsive High-risk non-muscle invasive bladder cancer (HRNMIBC) tumours have an ominous prognosis and require effective, tolerable treatments. Uptake remains low for FDA approved agents (including systemic pembrolizumab, nogapendekin alfa inbakicept-pmln or N-803) due to toxicity concerns. We hypothesize direct intravesical administration of a PDL1 inhibitor could be effective with less toxicity. However, it is unknown whether antibodies delivered via this route can...

10.1200/jco.2025.43.5_suppl.773 article EN Journal of Clinical Oncology 2025-02-10

Background Oral mucositis is a debilitating and painful complication of head neck cancer irradiation that characterised by inflammation the mucous membranes, erythema ulceration. affects 6000 patients per year in England Wales. Current treatments have not proven to be effective. International studies suggest low-level laser therapy may an effective treatment. Objectives To assess clinical effectiveness cost-effectiveness management oral irradiation. identify barriers facilitators...

10.3310/uwnb3375 article EN publisher-specific-oa Health Technology Assessment 2022-12-01

TPS710 Background: High-risk non-muscle invasive bladder cancer is a common and difficult to manage disease. The treatment of choice radical cystectomy (RC), as BCG-unresponsive tumours have poor prognosis. RC negatively impacts health related quality life therefore clinicians explored alternative treatments. FDA approved systemic pembrolizumab for BCG-refractory carcinoma in situ, but uptake low, reflecting concerns around efficacy safety non-invasive cancer. We hypothesize that...

10.1200/jco.2024.42.4_suppl.tps710 article EN Journal of Clinical Oncology 2024-01-29

Background The place of tonsillectomy in the management sore throat adults remains uncertain. Objectives To establish clinical effectiveness and cost-effectiveness tonsillectomy, compared with conservative management, for tonsillitis adults, to evaluate impact alternative patient pathways. Design This was a multicentre, randomised controlled trial comparing management. included qualitative process evaluation an economic evaluation. Setting study took at 27 NHS secondary care hospitals Great...

10.3310/ykur3660 article EN publisher-specific-oa Health Technology Assessment 2023-12-01
Coming Soon ...